Trial Profile
A Real-world Clinical Study on Effectiveness and Safety of Long-term TAF Treatment in Chronic Hepatitis B Patients in China
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Antivirals (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TRUE
- 14 Nov 2023 Interim results (n=404) assessing effectiveness and safety of TAF-based therapy in treatment naive or experienced CHB patients at 96 weeks, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 25 Nov 2019 Status changed from not yet recruiting to recruiting.
- 25 Nov 2019 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.